[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369201-105":59,"doc-detail-369201-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optimal-early-endpoint-for-second-line-or-subsequent-immune-checkpoint-inhibitors-in-previously-treated-advanced-solid-cancers-a-systematic-review","Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers - a systematic review","","Second-line or subsequent immune checkpoint inhibitors (ICIs) have been evaluated in previously treated patients with advanced solid cancers, but earlier trials lacked an appropriate primary efficacy endpoint. This systematic review identified the most optimal early efficacy endpoint for such studies by analyzing phase 2 or 3 trials with survival outcome data available from major databases before February 2023. Objective response rate (ORR) and progression-free survival (PFS) at 3, 6, and 9 months were compared for correlation with 12-month overall survival (OS).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optimal-early-endpoint-for-second-line-or-subsequent-immune-checkpoint-inhibitors-in-previously-treated-advanced-solid-cancers-a-systematic-review/369201/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optimal-early-endpoint-for-second-line-or-subsequent-immune-checkpoint-inhibitors-in-previously-treated-advanced-solid-cancers-a-systematic-review/369201.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question did this systematic review aim to answer?","Question",{"text":112,"@type":113},"It sought the most optimal early efficacy endpoint for trials testing second-line or subsequent ICIs in previously treated advanced solid cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which early efficacy measures were evaluated as potential endpoints?",{"text":117,"@type":113},"The review assessed objective response rate (ORR) and progression-free survival (PFS) at 3, 6, and 9 months as early efficacy candidates.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the review conclude about using early endpoints in randomized trials?",{"text":121,"@type":113},"Early efficacy endpoints are not recommended in RCTs to replace overall survival (OS), although 6-month PFS may serve as an early endpoint in non-randomized phase 2 settings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369201,1790940177,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Li etal. BMC Cancer (2025) 25:293  \n[https://doi.org/10.1186/s12885-025-13712-0](https://doi.org/10.1186/s12885-025-13712-0)  \nBMC Cancer  \n SYSTEMATIC REVIEW Open Access  \nOptimal early endpoint for second-line  \nor subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review  \nJingqiu Li1,2†, Xiaoding Zhou1,2†, Lei Wu1, Jiabao Ma1, Yan Tan1, Songke Wu3*, Jie Zhu1*, Qifeng Wang1* and Qiuling Shi4,5  \nAbstract  \nBackground The administration of second-line or subsequent immune checkpoint inhibitors (ICIs) in previously treated patients with advanced solid cancers has been clinically investigated. However, previous clinical trials lacked an appropriate primary endpoint for efficacy assessment. This systematic review aimed to explore the most optimal early efficacy endpoint for such trials.  \nMethods Phase 2 or 3 clinical trials involving patients with advanced solid cancers with disease progression following standard first-line therapy receiving second-line or subsequent ICI administration, with adequate survival outcome data, were included from PubMed, Embase, Web of Science, and Cochrane Library databases before February 2023. Quality assessment was conducted using the Cochrane tool and Newcastle–Ottawa Quality Assessment Scale for Cohort Studies for randomized controlled trials (RCTs) and non-randomized trials, respectively. Objective response rate (ORR) and progression-free survival (PFS) at 3, 6, and 9 months were investigated as potential early efficacy endpoint candidates for 12-month overall survival (OS), with a strong correlation defined as Pearson’s correlation coefficient r≥ 0.8.  \nResults A total of 64 RCTs comprising 22,725 patients and 106 non-randomized prospective trials involving 10,608 participants were eligible for modeling and external validation, respectively. RCTs examined 15 different cancer types, predominantly non-small-cell lung cancer (NSCLC) (17, 28%), melanoma (9, 14%), and esophageal squamous cell carcinoma (5, 8%) . The median sample size of RCTs was 124 patients, and the median follow-up time was 3.2–57.7 months. The ORR (r= 0 . 38; 95% confidence interval [CI], 0 .18–0. 54) and PFS (r= 0 .42; 95% CI, 0 .14–0. 64) exhibited weak trial-level correlations with OS. Within ICI treatment arms, the r values of ORR and 3-, 6-, and 9-month PFS with 12-month OS were 0.61 (95% CI, 0 .37–0. 79), 0.78 (95% CI, 0 .62–0. 88), 0.84 (95% CI, 0 .77–0. 90), and 0.86 (95%  \n†Jingqiu Li and Xiaoding Zhou contributed equally to this work.  \n*Correspondence: Songke Wu [13688013882@163.com](13688013882@163.com)[ ](13688013882@163.com)Jie Zhu [zhujiescch@163.com](zhujiescch@163.com)[ ](zhujiescch@163.com)Qifeng Wang [littlecancer@163.com](littlecancer@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nLi etal.","cbCaia4H4Hguf3Du","https://ap.wps.com/l/cbCaia4H4Hguf3Du","pdf",2084213,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What question did this systematic review aim to answer?\",\"answer\":\"It sought the most optimal early efficacy endpoint for trials testing second-line or subsequent ICIs in previously treated advanced solid cancers.\"},{\"question\":\"Which early efficacy measures were evaluated as potential endpoints?\",\"answer\":\"The review assessed objective response rate (ORR) and progression-free survival (PFS) at 3, 6, and 9 months as early efficacy candidates.\"},{\"question\":\"What did the review conclude about using early endpoints in randomized trials?\",\"answer\":\"Early efficacy endpoints are not recommended in RCTs to replace overall survival (OS), although 6-month PFS may serve as an early endpoint in non-randomized phase 2 settings.\"}]","Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers - a systematic review | PDF",1790181360,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e74a1cadf820729eca0cd100bdbfe61.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bbc3c1094446461b340967ca324c2c7.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f509a8b6662c3284256e163b6c94dd23.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41517c00419b3d138f1445dc19a18781.webp",980,1301]